Royalty Pharma plc
RPRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001802768
In the last 90 days, Royalty Pharma plc insiders filed 0 open-market purchases and 5 sales; 651 institutions reported holding it in 13F filings for Q2 2026, worth $20.6B in total; Dorsey Asset Management is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:22 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 11, 2026 | Jan 10, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B |
| Research and development | $452.0M | $2.00M | $52.0M | $177.1M | $200.1M |
| Selling, general and administrative | $573.5M | $236.7M | $249.7M | $227.3M | $182.8M |
| Operating income | $1.56B | $1.29B | $1.49B | $307.1M | $1.43B |
| Interest expense | – | – | $187.2M | $188.0M | $166.1M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | $770.9M | $859.0M | $1.13B | $42.8M | $619.7M |
| EPS, basic | $1.79 | $1.92 | $2.54 | $0.10 | $1.49 |
| EPS, diluted | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 |
| Weighted shares, basic | 429.8M | 448.2M | 447.6M | 438.0M | 414.8M |
| Weighted shares, diluted | 564.5M | 594.1M | 602.9M | 438.0M | 414.8M |
| Margins and growth | |||||
| Operating margin | 65.6% | 57.1% | 63.4% | 13.7% | 62.5% |
| Net margin | 32.4% | 37.9% | 48.2% | 1.9% | 27.1% |
| Revenue growth, year over year | +5.1% | −3.9% | +5.2% | −2.3% | +7.9% |
| Net income growth, year over year | −10.2% | −24.3% | +2,549.5% | −93.1% | −36.4% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 11, 2026 | Jan 10, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $618.7M | $929.0M | $477.0M | $1.71B | $1.54B |
| Total current assets | $1.53B | $1.80B | $1.27B | $2.55B | $2.88B |
| Goodwill | $924.6M | – | – | – | – |
| Intangible assets | – | – | – | $0 | $5.67M |
| Total assets | $19.6B | $18.2B | $16.4B | $16.8B | $17.5B |
| Short-term debt | $380.0M | $997.8M | $0 | $997.5M | $0 |
| Total current liabilities | $636.2M | $1.25B | $161.4M | $1.17B | $171.3M |
| Long-term debt | $8.57B | $6.61B | $6.14B | $6.12B | $7.10B |
| Total liabilities | $9.91B | $7.88B | $6.30B | $7.29B | $7.27B |
| Shareholders' equity | $9.71B | $10.3B | $10.1B | $9.53B | $10.2B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Feb 11, 2026 | Jan 10, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B |
| Stock-based compensation | $289.9M | $2.34M | $2.36M | $2.17M | $2.44M |
| Share buybacks | $1.23B | $229.7M | $304.8M | – | $0 |
| Investing cash flow | -$1.61B | -$2.68B | -$2.07B | -$1.03B | -$1.87B |
| Financing cash flow | -$1.19B | $361.1M | -$2.15B | -$944.9M | $385.1M |
| Net change in cash | -$310.3M | $452.0M | -$1.23B | $169.7M | $532.4M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 12.2% | 0.1% | 0.1% | 0.1% | 0.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.